These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 34013938)

  • 41. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system.
    Kim S; Wagner HN; Villemagne VL; Kao PF; Dannals RF; Ravert HT; Joh T; Dixon RB; Civelek AC
    J Nucl Med; 1997 Nov; 38(11):1726-31. PubMed ID: 9374341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Arachidonic acid inhibits inflammatory responses by binding to myeloid differentiation factor-2 (MD2) and preventing MD2/toll-like receptor 4 signaling activation.
    Zhang Y; Chen H; Zhang W; Cai Y; Shan P; Wu D; Zhang B; Liu H; Khan ZA; Liang G
    Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165683. PubMed ID: 31953218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors.
    Korpi ER; Linden AM; Hytönen HR; Paasikoski N; Vashchinkina E; Dudek M; Herr DR; Hyytiä P
    Addict Biol; 2017 Jul; 22(4):1022-1035. PubMed ID: 26990998
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nalmefene for the treatment of alcohol dependence: a current update.
    Soyka M
    Int J Neuropsychopharmacol; 2014 Apr; 17(4):675-84. PubMed ID: 24246244
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of positron emission tomography to measure the effects of nalmefene on D1 and D2 dopamine receptors in rat brain.
    Unterwald EM; Tsukada H; Kakiuchi T; Kosugi T; Nishiyama S; Kreek MJ
    Brain Res; 1997 Nov; 775(1-2):183-8. PubMed ID: 9439841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.
    Quelch DR; Mick I; McGonigle J; Ramos AC; Flechais RSA; Bolstridge M; Rabiner E; Wall MB; Newbould RD; Steiniger-Brach B; van den Berg F; Boyce M; Østergaard Nilausen D; Breuning Sluth L; Meulien D; von der Goltz C; Nutt D; Lingford-Hughes A
    Biol Psychiatry; 2017 Jun; 81(11):941-948. PubMed ID: 28216062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lovastatin inhibits Toll-like receptor 4 signaling in microglia by targeting its co-receptor myeloid differentiation protein 2 and attenuates neuropathic pain.
    Peng Y; Zhang X; Zhang T; Grace PM; Li H; Wang Y; Li H; Chen H; Watkins LR; Hutchinson MR; Yin H; Wang X
    Brain Behav Immun; 2019 Nov; 82():432-444. PubMed ID: 31542403
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors.
    DeHaven-Hudkins DL; Brostrom PA; Allen JT; Lesko LJ; Ferkany JW; Kaplita PV; Mavunkel BJ; Rzeszotarski WJ; Steranka LR
    Pharmacol Biochem Behav; 1990 Nov; 37(3):497-504. PubMed ID: 1965042
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Folic acid derived-P5779 mimetics regulate DAMP-mediated inflammation through disruption of HMGB1:TLR4:MD-2 axes.
    Sun S; He M; Wang Y; Yang H; Al-Abed Y
    PLoS One; 2018; 13(2):e0193028. PubMed ID: 29447234
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A polar SxxS motif drives assembly of the transmembrane domains of Toll-like receptor 4.
    Kargas V; Marzinek JK; Holdbrook DA; Yin H; Ford RC; Bond PJ
    Biochim Biophys Acta Biomembr; 2017 Oct; 1859(10):2086-2095. PubMed ID: 28739292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myeloid differentiation protein 2 induced retinal ischemia reperfusion injury via upregulation of ROS through a TLR4-NOX4 pathway.
    Chen H; Song Z; Ying S; Yang X; Wu W; Tan Q; Ju X; Wu W; Zhang X; Qu J; Wang Y
    Toxicol Lett; 2018 Jan; 282():109-120. PubMed ID: 29111459
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prolonged blockade of opioid effect with oral nalmefene.
    Gal TJ; DiFazio CA; Dixon R
    Clin Pharmacol Ther; 1986 Nov; 40(5):537-42. PubMed ID: 3533370
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose.
    Kaplan JL; Marx JA; Calabro JJ; Gin-Shaw SL; Spiller JD; Spivey WL; Gaddis GM; Zhao N; Harchelroad FP
    Ann Emerg Med; 1999 Jul; 34(1):42-50. PubMed ID: 10381993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human pharmacology and abuse potential of nalmefene.
    Fudala PJ; Heishman SJ; Henningfield JE; Johnson RE
    Clin Pharmacol Ther; 1991 Mar; 49(3):300-6. PubMed ID: 2007323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potential Roles of Myeloid Differentiation Factor 2 on Neuroinflammation and Its Possible Interventions.
    Oo TT; Pratchayasakul W; Chattipakorn N; Chattipakorn SC
    Mol Neurobiol; 2020 Nov; 57(11):4825-4844. PubMed ID: 32803490
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model.
    Callaghan CK; Rouine J; Dean RL; Knapp BI; Bidlack JM; Deaver DR; O'Mara SM
    Brain Behav Immun; 2018 Jan; 67():152-162. PubMed ID: 28844812
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emodin ameliorated lipopolysaccharide-induced fulminant hepatic failure by blockade of TLR4/MD2 complex expression in D-galactosamine-sensitized mice.
    Yin X; Gong X; Jiang R; Kuang G; Wang B; Zhang L; Xu G; Wan J
    Int Immunopharmacol; 2014 Nov; 23(1):66-72. PubMed ID: 25173984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gedunin Binds to Myeloid Differentiation Protein 2 and Impairs Lipopolysaccharide-Induced Toll-Like Receptor 4 Signaling in Macrophages.
    Borges PV; Moret KH; Maya-Monteiro CM; Souza-Silva F; Alves CR; Batista PR; Caffarena ER; Pacheco P; Henriques Md; Penido C
    Mol Pharmacol; 2015 Nov; 88(5):949-61. PubMed ID: 26330549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.